Company Overview and News

1
Airbus set to close deal for majority stake in Bombardier Cseries

2018-06-08 channelnewsasia
Airbus SE is set to close a deal to take a controlling stake in Bombardier Inc's CSeries jetliner program, effective July 1, the companies said on Friday, in a move expected to kickstart the European planemaker's ability to put its marketing and cost-cutting muscle into the Canadian plane program.
BDRPF QBC

1
Airbus set to close deal for majority stake in Bombardier Cseries

2018-06-08 reuters
(Reuters) - Airbus SE (AIR.PA) is set to close a deal to take a controlling stake in Bombardier Inc’s (BBDb.TO) CSeries jetliner program, effective July 1, the companies said on Friday, in a move expected to kickstart the European planemaker’s ability to put its marketing and cost-cutting muscle into the Canadian plane program.
BDRPF QBC

1
Airbus set to close deal for majority stake in Bombardier Cseries

2018-06-08 reuters
June 8 (Reuters) - Airbus SE is set to close a deal to take a controlling stake in Bombardier Inc’s CSeries jetliner program, effective July 1, the companies said on Friday, in a move expected to kickstart the European planemaker’s ability to put its marketing and cost-cutting muscle into the Canadian plane program.
BDRPF QBC

1
Quebec abandons plans for pit bull ban, citing lack of science to back breed-specific laws

2018-06-06 thestar
This copy is for your personal non-commercial use only. To order presentation-ready copies of Toronto Star content for distribution to colleagues, clients or customers, or inquire about permissions/licensing, please go to: www.TorontoStarReprints.com
QBC

1
Questerre condemns short term election politics in Quebec

2018-06-06 globenewswire
THIS NEWS RELEASE IS NOT FOR DISSEMINATION OR DISTRIBUTION IN THE UNITED STATES OF AMERICA TO UNITED STATES NEWSWIRE SERVICES OR UNITED STATES PERSONS
QEC QBC QTEYF

1
Quebec offers financial support to aluminum producers hurt by U.S. tariffs

2018-06-04 cbc.ca
The Quebec government is prepared to financially support smaller aluminum producers hurt by U.S. tariffs just as it did with the softwood lumber sector, the province's economic development minister said Monday.
QBC

1
Less condoms, more online hookups: Experts say STIs are on the rise in Canada

2018-05-29 thestar
This copy is for your personal non-commercial use only. To order presentation-ready copies of Toronto Star content for distribution to colleagues, clients or customers, or inquire about permissions/licensing, please go to: www.TorontoStarReprints.com
QBC

1
Canada puts asylum seekers to work as system feels pressure

2018-05-21 thestar
This copy is for your personal non-commercial use only. To order presentation-ready copies of Toronto Star content for distribution to colleagues, clients or customers, or inquire about permissions/licensing, please go to: www.TorontoStarReprints.com
QBC

1
Quebec seeks power to collect federal taxes to allow residents to file only one return

2018-05-18 thestar
This copy is for your personal non-commercial use only. To order presentation-ready copies of Toronto Star content for distribution to colleagues, clients or customers, or inquire about permissions/licensing, please go to: www.TorontoStarReprints.com
QBC

1
Door will open to genetic discrimination if act protecting Canadians is overturned, genomics expert says

2018-05-14 cbc.ca
Medical researcher Yvonne Bombard is worried about a future where Canadians could face increasing discrimination based on their genetic profiles.
QBC

1
Bill 62: Quebec releases criteria for requesting religious accommodation

2018-05-09 cbc.ca
The Quebec government has released its guidelines on how it will assess requests for religious accommodation under Bill 62, the law concerning face coverings and use of public services.
QBC

1
Federal Immigration Minister warns seeking asylum in Canada is ‘no free ticket’

2018-05-08 thestar
This copy is for your personal non-commercial use only. To order presentation-ready copies of Toronto Star content for distribution to colleagues, clients or customers, or inquire about permissions/licensing, please go to: www.TorontoStarReprints.com
QBC

1
This doctor was jailed for child porn. Then Quebec gave him a licence

2018-05-03 thestar
This copy is for your personal non-commercial use only. To order presentation-ready copies of Toronto Star content for distribution to colleagues, clients or customers, or inquire about permissions/licensing, please go to: www.TorontoStarReprints.com
QBC

1
After consulting mediums, Quebec parents of missing man return to Vancouver to restart search

2018-05-01 cbc.ca
The Quebec parents of missing hiker Carl Couture are making another effort to find their son after a number of mediums told them he may still be alive.
QBC

6
Strategic investment by Goldcorp to create a new gold explorer in the Eeyou Istchee James Bay territory of Quebec with Canada Strategic Metals, Matamec Explorations and Sphinx Resources

2018-04-26 globenewswire
MONTREAL, April 26, 2018 (GLOBE NEWSWIRE) -- Matamec Explorations Inc. (“Matamec”) (TSX-V:MAT), Canada Strategic Metals Inc. (“Canada Strategic”) (TSX-V:CJC) and Sphinx Resources Ltd. (“Sphinx”) (TSX-V:SFX) are pleased to announce that Canada Strategic and Matamec have agreed to a business combination by way of court approved plan of arrangement (the “Arrangement”) to create a new James Bay-focused gold exploration company (to be named Quebec Precious Metals Corporation (the “Name Change”), herein referred to as “QPM”).
SOI CJCFF SIREF TYHOF SFX DRGDF QBC MAT MHREF DONFF DGC CJC 8015 GG

Related Articles

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

2018-06-18 - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

PRTO: Proteon Therapeutics Analysis and Research Report

2018-06-11 - Asif

Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...

GALE: Galena Biopharma Analysis and Research Report

2018-06-11 - Asif

Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...

Silicon Investor Message Boards

This table lists all message boards related to ASX:QBC / QUEBEC on message board site Silicon Investor.

Buying QBC